Funding & VC

Neobe Raises $6.8 Million to Send Engineered Bacteria Into Solid Tumors

Neobe Therapeutics raised $6.8 million in seed funding led by ARC Ventures, bringing total funding past $10.5 million as it advances engineered bacteria toward a 2028 IND filing.

By Grace Kim

3 min read

Neobe Raises $6.8 Million To Advance Engineered Bacteria For Solid Tumors
Neobe Raises $6.8 Million To Advance Engineered Bacteria For Solid TumorsDarkoStojanovic / pixabay

What's News

  • Neobe Therapeutics raised $6.8 million in seed financing led by ARC Ventures, bringing total funding above $10.5 million.
  • Lead program NEO22 targets an investigational new drug filing in 2028, with an additional tranche expected to fund a first human study.
  • A 2026 Molecular Cancer Therapeutics paper showed a single dose of engineered bacteria produced complete tumor regression in one triple-negative breast cancer model.
  • Dr. Laura Chow joined as chief medical officer to oversee first-in-human trial preparations.
  • Neobe was founded in 2021; existing investor 2048 Ventures participated in the round.

Neobe Therapeutics has raised $6.8 million in seed financing to advance engineered bacterial medicines that break down the physical barriers blocking cancer treatments from reaching solid tumors. ARC Ventures led the round, with Faber, Macmillan Ventures, Proven Connect and Empirical Ventures joining existing investor 2048 Ventures. The financing lifts Neobe's total funding to more than $10.5 million.

The London-based biotech, founded in 2021, will spend the capital pushing its lead program, NEO22, through preclinical development and toward an investigational new drug filing in 2028. An additional tranche of the seed round is expected to finance a first human study.

Co-founder and CEO Dr. Pedro Correa de Sampaio framed the problem in blunt terms: "Several treatments that can cure cancer already exist, but in far too many patients they simply cannot get to where they are needed. I'm delighted to be working with investors that share our vision of making untreatable cancers curable, and excited to move our platform towards clinical trials."

Why can't drugs reach solid tumors?

Immunotherapies and other modern cancer medicines have improved outcomes for many patients — but only when they can actually get inside the tumor. Some solid tumors sit behind a dense, fibrous matrix that functions as a wall, keeping drugs and immune cells away from cancer cells even when the treatment has the right biological target.

Neobe's answer is to reprogram harmless strains of common bacteria into living medicines. After injection, the bacteria are designed to travel to tumors and release enzymes that dissolve components of the surrounding matrix.

The goal is not to kill cancer cells directly. Neobe wants to open the door so immune cells and other therapies can walk through, potentially improving the effectiveness of treatments that already exist. That's the whole thesis in one line: make resistant tumors responsive again.

What did the preclinical data show?

The evidence so far comes from a 2026 paper in Molecular Cancer Therapeutics, produced with researchers from the University of Cyprus and Barts Cancer Institute in London. The team tested Neobe's engineered bacterial platform in a model of triple-negative breast cancer that had stopped responding to a commonly used combination of immunotherapy drugs.

According to Neobe, a single dose of its engineered bacteria produced complete tumor regression in response to that same immunotherapy in one of the models studied. Months later, when the model was exposed to the same cancer again, no additional tumors developed — a result the researchers said suggested the formation of lasting antitumor immune memory.

The caveats are real. The findings come from preclinical models and do not establish that the approach will be safe or effective in people. NEO22 still needs to clear additional laboratory studies and regulatory review before any clinical testing can begin.

Who is building the clinical team?

Neobe recently appointed immuno-oncology specialist Dr. Laura Chow as chief medical officer. Chow will oversee clinical development and preparations for a first-in-human trial, adding clinical leadership as the company shifts from platform research to the regulatory and operational demands of human studies.

The investor syndicate made its positioning explicit. Joseph Korff, founder of ARC Ventures, said: "We are excited to back Neobe Therapeutics' differentiated approach to overcoming the physical barriers created by dense tumour matrices. Assets derived from Neobe's platform will improve the efficacy of cancer therapies and extend their benefits to more patients."

Felix Litzkow, head of Macmillan Ventures, pointed to the fit with his organization's patient-driven mission: "We are very proud to be supporting Neobe, and to be helping create the right environment for such promising new cancer care solutions to thrive."

Dr. Julie Wolf, partner at 2048 Ventures, which backed Neobe at pre-seed, said the founders' mission — "to make life-saving drugs available and effective for all patients, regardless of the tumour microenvironment" — has always resonated with her firm.

The next milestones are fixed and dated: NEO22 through preclinical development, an IND filing in 2028, and an initial human study funded by the expected follow-on tranche.

Source: pulse2.com

Share this article:

More from Grace Kim

Grace Kim

Show full bio

Market editor covering people, launches and day-to-day practice in entrepreneurship, startups and venture funding at Business Bearings.

2,301 articles

Related articles

« Previous articleNext article »